INITIAL

Ultimovac's study in malignant melanoma is fully recruited

Despite challenges related to the pandemic, Norwegian biotechnology company Ultimovacs can now show progress in the clinical trial of malignant melanoma....

Ultimovacs in the wind ahead of 2022

In Ultimovac's recently published report for the fourth...

Intervju

Ultimovacs receives orphan drug designation for UV1

Last week, it was announced that Ultimovac's universal cancer vaccine...

Ultimovacs receives double Fast Track for UV1

Ultimovac's work on developing a cancer vaccine was...

Strengthened clinical validation of Ultimovacs UV1 in the second quarter

For Norwegian Ultimovacs, the second quarter of the year was about...

Intervju

Ultimovacs presents study design for INITIUM at AACR

Last week, the American Association for Cancer Research launched...

Ultimovacs initiates fourth phase II study with UV1

Christmas Eve came early to Ultimovacs when the company was able to...

Ultimovacs takes up the fight against melanoma

Melanoma is the deadliest form of skin cancer and...

Ultimovac's path towards a universal cancer vaccine

Cancers represent a heavy burden on society and...